These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37385337)

  • 1. Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma.
    Oppenheimer J; Hanania NA; Chaudhuri R; Sagara H; Bailes Z; Fowler A; Peachey G; Pizzichini E; Slade D
    Chest; 2023 Nov; 164(5):1087-1096. PubMed ID: 37385337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
    Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
    Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
    Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
    Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids.
    Kerwin E; Pascoe S; Bailes Z; Nathan R; Bernstein D; Dahl R; von Maltzahn R; Robbins K; Fowler A; Lee L
    Respir Res; 2020 Jun; 21(1):148. PubMed ID: 32532275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
    Lipson DA; Birk R; Brealey N; Zhu CQ
    Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.
    Pascoe S; Barnes N; Brusselle G; Compton C; Criner GJ; Dransfield MT; Halpin DMG; Han MK; Hartley B; Lange P; Lettis S; Lipson DA; Lomas DA; Martinez FJ; Papi A; Roche N; van der Valk RJP; Wise R; Singh D
    Lancet Respir Med; 2019 Sep; 7(9):745-756. PubMed ID: 31281061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
    Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
    Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial.
    Bleecker ER; Lötvall J; O'Byrne PM; Woodcock A; Busse WW; Kerwin EM; Forth R; Medley HV; Nunn C; Jacques L; Bateman ED
    J Allergy Clin Immunol Pract; 2014; 2(5):553-61. PubMed ID: 25213048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Vestbo J; Anderson JA; Brook RD; Calverley PM; Celli BR; Crim C; Martinez F; Yates J; Newby DE;
    Lancet; 2016 Apr; 387(10030):1817-26. PubMed ID: 27203508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised, double-blind, placebo-controlled, cross-over single dose study of the bronchodilator duration of action of combination fluticasone furoate/vilanterol inhaler in adult asthma.
    Braithwaite I; Williams M; Power S; Pilcher J; Weatherall M; Baines A; Moynihan J; Kempsford R; Beasley R;
    Respir Med; 2016 Oct; 119():115-121. PubMed ID: 27692131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM; Maspero J; Chapman KR; van Zyl-Smit RN; Hosoe M; Tanase AM; Lavecchia C; Pethe A; Shu X; D'Andrea P;
    Lancet Respir Med; 2020 Oct; 8(10):1000-1012. PubMed ID: 32653074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA.
    Bernstein D; Andersen L; Forth R; Jacques L; Yates L
    J Asthma; 2018 Sep; 55(9):984-993. PubMed ID: 28961020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, double-blind trial evaluating the efficacy and safety of fluticasone propionate and fluticasone propionate/salmeterol delivered via multidose dry powder inhalers in patients with persistent asthma aged 12 years and older.
    Raphael G; Yiu G; Sakov A; Liu S; Caracta C
    J Asthma; 2018 Jun; 55(6):640-650. PubMed ID: 28763243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Woodcock A; Vestbo J; Bakerly ND; New J; Gibson JM; McCorkindale S; Jones R; Collier S; Lay-Flurrie J; Frith L; Jacques L; Fletcher JL; Harvey C; Svedsater H; Leather D;
    Lancet; 2017 Nov; 390(10109):2247-2255. PubMed ID: 28903864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
    Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
    Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
    Yang S; Lee LA; Sule N; Fowler A; Peachey G
    Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial.
    Brightling CE; Chanez P; Leigh R; O'Byrne PM; Korn S; She D; May RD; Streicher K; Ranade K; Piper E
    Lancet Respir Med; 2015 Sep; 3(9):692-701. PubMed ID: 26231288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of fluticasone furoate/umeclidinium in adult patients with asthma: a randomized, dose-ranging study.
    Lee LA; Yang S; Kerwin E; Trivedi R; Edwards LD; Pascoe S
    Respir Med; 2015 Jan; 109(1):54-62. PubMed ID: 25452139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of umeclidinium on lung function and symptoms in patients with fixed airflow obstruction and reversibility to salbutamol: A randomised, 3-phase study.
    Lee L; Kerwin E; Collison K; Nelsen L; Wu W; Yang S; Pascoe S
    Respir Med; 2017 Oct; 131():148-157. PubMed ID: 28947022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.